Skip to Main Content

Faculty & Researchers

  • Assistant Professor Adjunct, Radiology & Biomedical Imaging

    Dr. Lin received the B.S. degree from Rensselaer Polytechnic Institute and the Ph.D. degree from Duke University, all in biomedical engineering. He is currently the Director for Clinical Research in North America for Visage Imaging and is stationed at Yale-New Haven Hospital where he oversees, coordinates, drives and directs research collaborations with high profile academic hospitals in North America to develop new solutions for diagnostic image analysis and guidance that improve clinical and operational outcomes while reducing cost of care. This includes activities in Artificial Intelligence (AI) and Machine Learning (ML) in the Radiology enterprise diagnostic imaging solutions space. Dr. Lin identifies opportunities for academic-industry research partnerships, and acts as the liaison between Visage Imaging researchers and clinical collaborators to translate ideas to prototype for clinical validation, with the goal of technology transfer to product. A highlight is Ming coordinated the clinical data curation and ground-truth annotation for building a fully automatic breast density AI classifier that provides an ACR BI-RADS Atlas 5th Edition breast density category to aid radiologists in the assessment of breast tissue composition from full field digital mammography and digital breast tomosynthesis systems and drove the clinical validation with Yale radiologists and Visage developers that led to transfer to product and regulatory approvals in 21 months. Notably, this was the first for a major PACS vendor to offer a self-developed, FDA-cleared AI algorithm natively into their PACS: Visage Breast Density, K201411, 510(k) clearance, January 2021, Health Canada Licensed, October 2020, Australian TGA approval, July 2020, CE Mark Cleared, May 2020.


    Dr. Lin also is directly involved in research to develop better ways to treat patients with liver cancer using transcatheter arterial chemoembolization (TACE) and in this context, he is also the chief engineer and operations manager of the Yale Interventional Oncology Research Lab. Dr. Lin is the Principle Investigator (PI) on two NIH R01 grants to improve the diagnosis, treatment, and response assessment after transcatheter arterial chemoembolization for patients with liver cancer. Dr. Lin is the inventor of 3D quantification TACE therapy response tool (qEASL) and in collaboration with clinical partners, validated, and showed clinical relevance (ability to predict patient survival) that led to transfer to commercial product (FDA 510(k) cleared December 2016 - Multi-Modality Tumor Tracking (MMTT) application). Prior to Visage Imaging, Dr. Lin was the Philips research site manager and senior researcher stationed onsite at Yale where he managed the research portfolio and partnership Philips has with Yale.

  • Assistant Professor; Resident in Radiology and Biomedical Imaging

    Dr. Chapiro joined the Department of Radiology and Biomedical Imaging as a research scientist and interventional radiology resident from Berlin, Germany. After graduating from the University of Leipzig and upon completion of his research thesis at the Justus-Liebig University in Giessen with summa cum laude, he served as a postdoctoral research fellow in interventional oncology at The Johns Hopkins Hospital and then as radiology resident at the Department of Radiology, Charité University Hospital in Berlin.

    Dr. Chapiro’s research focuses on developing new quantitative imaging biomarkers for the diagnosis, characterization, and therapeutic management of liver cancer. His translational research portfolio includes the development of novel embolic agents as well as the application of artificial intelligence solutions for the management of liver cancer. His basic research interest mainly focuses on developing new tools to characterize the tumor microenvironment and the immune system in the setting of loco-regional, image-guided therapies of liver cancer.

    Creating innovative and clinically applicable imaging solutions for liver cancer with advanced molecular imaging, image post-processing and machine learning approaches and translating them to clinical practice has been his central mission for the past decade. He authored and co-authored >100 original research articles, reviews and book chapters and gave more than 70 talks and invited lectures within the last five years. His research has also resulted in several patents, 510(k)-approved medical products and significant grant support from federal, foundational and industry sources. He is an active research mentor to more than 30 undergraduate, medical and graduate students as well as peers both at Yale and other national and international institutions. Being an active contributor, journal-, abstract- and grant reviewer in several professional societies (RSNA, SIR and SIO), he is also committed to education and the mission of disseminating research data and scientific knowledge. Dr. Chapiro consults the Editorial Board of the Journal of Hepatology, is a member of the American College of Radiology Liver Imaging Reporting and Data System (LI-RADS) Steering Committee, he additionally serves on the Society of Interventional Oncology Research Committee and is the incoming Chair of the Annual Meeting Program Planning Committee for the Subspecialty of Interventional Radiology at the Annual Radiological Society of North America meeting 2021-2023. He is the co-initiator of the "Rising Star" Student Exchange Program in collaboration with the Charité University Hospital in Berlin and co-directs the Yale Interventional Oncology Research Laboratory. Dr. Chapiro is the Associate Director of the Clinical and Translational Core of the Yale Liver Center. 

  • Research Associate, Radiology

    Eliot Funai graduated from the University of Maryland, Baltimore County, and previously worked at Johns Hopkins University before coming to Yale. His work as a clinical research coordinator is to develop and oversee the management and execution of clinical trials, primarily concerning locoregional therapies for treating liver cancers. His experience is with investigator initiated studies, industry and NIH-funded trials, and cooperative group studies.

  • Simon Iseke joined the Department of Radiology and Biomedical Imaging at Yale in October 2019 as a Postgraduate Associate within the “Rising Star” Research Exchange Program between the Charité University Hospital Berlin, Germany and the Yale School of Medicine. Simon is a 3rd-year medical student at the University Hospital Rostock and received a travel grant from the Rolf W. Günther Foundation for Radiological Sciences.
  • Medical Student

    Mansur Ghani is a third year medical student at Yale School of Medicine. Since joining the group in 2015, Mansur's work has involved predicting response to treatment of HCC to intra-arterial therapy and investigating staging biomarkers for colorectal cancer metastases to the liver. He currently holds a BS in Molecular Biophysics and Biochemistry from Yale College, and plans to apply for residency programs in interventional radiology.
  • Moritz Gross joined the Yale Interventional Oncology Research Lab in October 2019 as a Postgraduate Associate within the “Rising Star” Research Exchange Program in collaboration with the Charité University Berlin, where he is a 4th-year medical student.

    His current research at the Yale Interventional Oncology Research Lab focuses on Machine Learning.

    For his travel to Yale, he received a travel grant from the Rolf W. Günther Foundation for Radiological Sciences.

    Moreover, he is part of the Noninvasive Imaging Heisenberg Research Group of Prof. Dr. Marc Dewey at Charité in Berlin, where he is researching on noninvasive cardiovascular imaging research.

  • Medical Student

    Medical Student at Yale School of Medicine. Studied Neurobiology, Physiology, and Behavior in his home state at the University of California, Davis. Research experience in interventional radiology, diagnostic radiology, and addiction medicine. Currently investigating the effects of intra-arterial embolic therapies such as chemoembolization, drug-eluting bead embolization, and radioembolization in the treatment of hepatocellular carcinoma and metastatic liver tumors. Other ongoing research includes investigation of the role of multiparametric MRI in the diagnosis of prostate cancer.